We at BIO share the global concern about the spread of Influenza A(H1N1). It is critical to be prepared but not panicked.
2009 BIO International Convention and Influenza A(H1N1) - Swine Flu
We continue to monitor closely information and guidance from federal and international agencies concerning the Influenza A (H1N1) outbreak in the United States. We remain committed to providing our attendees with timely travel advisories and other information. For more information convention.bio.org
For General Influenza A (H1N1) - Swine Flu Updates:
The World Health Organization states that influenza viruses are not known to be transmissible to people through eating processed pork or other food products derived from pigs. WHO statement on influenza A(H1N1) and the safety of pork
Contact us to find out more about why biotech treatments are uniquely effective to treat viruses like swine flu.
Senate Judiciary Committee Approves Compromise on Patent Reform
On April 2nd, the Senate Judiciary Committee approved a compromise amendment to S. 515, the Patent Reform Act. We appreciate the tireless efforts of Senators Patrick Leahy (D, VT), Dianne Feinstein (D, CA) and Arlen Specter (R, PA) to craft careful compromises on several key issues, including damages and post-grant review. Patent reform was one of the key issues addressed by the more than 250 biotechnology industry representatives from 36 states who participated in hundreds of meetings with key Members of the House and Senate as part of BIO’s Legislative Fly-In earlier this week.
Nominations for the First Annual Biotech Humanitarian Award Close on April 15, 2009
The Biotech Humanitarian Award will be given to an everyday hero in the field of biotechnology who has improved the lives of others by harnessing the power of biotech to help feed, fuel and heal the planet. The Biotech Humanitarian Award winner will be recognized at the 2009 BIO International Convention in Atlanta and will receive an award $10,000. You can nominate anyone in the biotechnology industry including advocates, scientists, researchers, academics, entrepreneurs, financiers, philanthropists, educators and others.
Nominations must be submitted by April 15, 2009 and can be made online at www.iambiotech.org.
Bipartisan Pathway to Biosimilars Act will lead to real solutions for our nation's health care challenges and provide real hope for patients.
H.R. 1548, the Pathway to Biosimilars Act, introduced by Representatives Anna Eshoo (D-CA), Jay Inslee (D-WA) and Joe Barton (R-TX) lays out an effective, reasonable and safe pathway to biosimilars. It is the right medicine for lowering costs, ensuring patient safety and providing fair, responsible incentives for continued biotech research into cures for deadly and debilitating diseases.
